Understanding heart failure with preserved ejection fraction: Clinical importance and future outlook

Alan B. Miller, Ileana L. Pina

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Heart failure (HF) with preserved ejection fraction (HF-PEF) accounts for approximately one half of all HF patients admitted with acute decompensated HF and carries a significant morbidity and mortality burden. This condition, however, has been largely understudied because it is difficult to diagnose, and management guidelines are still being discussed. This article provides an overview of HF-PEF and its pathophysiology, diagnosis, and treatment, with a focus on clinical trials using renin-angiotensin-aldosterone system (RAAS) blockers. Inhibitors of the RAAS have been studied in HF-PEF to determine whether their benefits extend beyond blood pressure control. However, the 3 trials conducted to date (CHARM-Preserved, PEP-CHF, and I-PRESERVE) with candesartan, perindopril, and irbesartan, have failed to demonstrate significant morbidity and mortality benefits. Although no agent has proven statistically significant benefits in morbidity and mortality in HF-PEF, recent studies have added to the breadth of clinical data and understanding of the demographics of these patients.

Original languageEnglish (US)
Pages (from-to)186-192
Number of pages7
JournalCongestive Heart Failure
Volume15
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Heart Failure
irbesartan
Renin-Angiotensin System
Morbidity
Mortality
Perindopril
Demography
Clinical Trials
Guidelines
Blood Pressure
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Emergency Medicine
  • Emergency

Cite this

Understanding heart failure with preserved ejection fraction : Clinical importance and future outlook. / Miller, Alan B.; Pina, Ileana L.

In: Congestive Heart Failure, Vol. 15, No. 4, 2009, p. 186-192.

Research output: Contribution to journalArticle

@article{0d9a1932b3244747a697d93f18ea699e,
title = "Understanding heart failure with preserved ejection fraction: Clinical importance and future outlook",
abstract = "Heart failure (HF) with preserved ejection fraction (HF-PEF) accounts for approximately one half of all HF patients admitted with acute decompensated HF and carries a significant morbidity and mortality burden. This condition, however, has been largely understudied because it is difficult to diagnose, and management guidelines are still being discussed. This article provides an overview of HF-PEF and its pathophysiology, diagnosis, and treatment, with a focus on clinical trials using renin-angiotensin-aldosterone system (RAAS) blockers. Inhibitors of the RAAS have been studied in HF-PEF to determine whether their benefits extend beyond blood pressure control. However, the 3 trials conducted to date (CHARM-Preserved, PEP-CHF, and I-PRESERVE) with candesartan, perindopril, and irbesartan, have failed to demonstrate significant morbidity and mortality benefits. Although no agent has proven statistically significant benefits in morbidity and mortality in HF-PEF, recent studies have added to the breadth of clinical data and understanding of the demographics of these patients.",
author = "Miller, {Alan B.} and Pina, {Ileana L.}",
year = "2009",
doi = "10.1111/j.1751-7133.2009.00063.x",
language = "English (US)",
volume = "15",
pages = "186--192",
journal = "Congestive Heart Failure",
issn = "1527-5299",
publisher = "Le Jacq Communications, Inc.",
number = "4",

}

TY - JOUR

T1 - Understanding heart failure with preserved ejection fraction

T2 - Clinical importance and future outlook

AU - Miller, Alan B.

AU - Pina, Ileana L.

PY - 2009

Y1 - 2009

N2 - Heart failure (HF) with preserved ejection fraction (HF-PEF) accounts for approximately one half of all HF patients admitted with acute decompensated HF and carries a significant morbidity and mortality burden. This condition, however, has been largely understudied because it is difficult to diagnose, and management guidelines are still being discussed. This article provides an overview of HF-PEF and its pathophysiology, diagnosis, and treatment, with a focus on clinical trials using renin-angiotensin-aldosterone system (RAAS) blockers. Inhibitors of the RAAS have been studied in HF-PEF to determine whether their benefits extend beyond blood pressure control. However, the 3 trials conducted to date (CHARM-Preserved, PEP-CHF, and I-PRESERVE) with candesartan, perindopril, and irbesartan, have failed to demonstrate significant morbidity and mortality benefits. Although no agent has proven statistically significant benefits in morbidity and mortality in HF-PEF, recent studies have added to the breadth of clinical data and understanding of the demographics of these patients.

AB - Heart failure (HF) with preserved ejection fraction (HF-PEF) accounts for approximately one half of all HF patients admitted with acute decompensated HF and carries a significant morbidity and mortality burden. This condition, however, has been largely understudied because it is difficult to diagnose, and management guidelines are still being discussed. This article provides an overview of HF-PEF and its pathophysiology, diagnosis, and treatment, with a focus on clinical trials using renin-angiotensin-aldosterone system (RAAS) blockers. Inhibitors of the RAAS have been studied in HF-PEF to determine whether their benefits extend beyond blood pressure control. However, the 3 trials conducted to date (CHARM-Preserved, PEP-CHF, and I-PRESERVE) with candesartan, perindopril, and irbesartan, have failed to demonstrate significant morbidity and mortality benefits. Although no agent has proven statistically significant benefits in morbidity and mortality in HF-PEF, recent studies have added to the breadth of clinical data and understanding of the demographics of these patients.

UR - http://www.scopus.com/inward/record.url?scp=67651162426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651162426&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7133.2009.00063.x

DO - 10.1111/j.1751-7133.2009.00063.x

M3 - Article

C2 - 19627293

AN - SCOPUS:67651162426

VL - 15

SP - 186

EP - 192

JO - Congestive Heart Failure

JF - Congestive Heart Failure

SN - 1527-5299

IS - 4

ER -